Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A prospective randomized double-blind clinical trial by Ruggenenti, Piero et al.
Effects of Combined Ezetimibe and
Simvastatin Therapy as Compared With
Simvastatin Alone in Patients With Type 2
Diabetes























GIUSEPPE REMUZZI, MD, FRCP
1,2
FOR THE EZETIMIBE AND SIMVASTATIN IN
DYSLIPIDEMIA OF DIABETES (ESD)
STUDY GROUP*
OBJECTIVE — To assess the effects of inhibited gastrointestinal cholesterol absorption in
statin-treated dyslipidemic patients.
RESEARCH DESIGN AND METHODS — In a multicenter prospective randomized
double-blind placebo-controlled trial, we primarily compared by ANCOVA the effect of
2-month ezetimibe (10 mg/day) or placebo therapy on LDL cholesterol serum levels in 108 type
2 diabetic patients with albuminuria 200 g/min and total cholesterol concentrations 135
mg/dl despite simvastatin treatment (40 mg/day).
RESULTS — Unlike placebo, ezetimibe decreased LDL cholesterol from 99  31 to 66  22
mg/dl, total cholesterol from 162  36 to 124  30 mg/dl, and apolipoprotein B from 83  22
to 64  18 mg/dl (P  0.0001 for all changes versus placebo). A total of 72 and 17% of patients
on ezetimibe or placebo achieved LDL levels 70 mg/dl, respectively (P  0.0001). Treatment
was well tolerated.
CONCLUSIONS — Adding ezetimibe to simvastatin therapy helps to improve the pro-
atherogenic lipoprotein proﬁle in type 2 diabetic patients who fail to reach recommended lipid
targets with statin therapy alone.
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I
nhibited gastrointestinal cholesterol
absorption by add-on ezetimibe ther-
apy (1) reduced cholesterol levels in
patients with persistent dyslipidemia de-
spite statin therapy (1–6). Advantages of
dual- versus single-drug lipid-lowering
therapy, however, could not be deﬁnitely
established, since the effects of ezetimibe
combined with a given dosage of a statin
were compared with those of mono-
therapy with another competitor statin
(4,5) or even with the same statin but
given at higher dosages (2). To address
this issue, the Ezetimibe and Simvasta-
tin in Dyslipidemia of Diabetes (ESD)
study (ClinicalTrials.gov identiﬁer:
NCT00157482) compared the lipid-
lowering effects of ezetimibe or placebo
added on the same background statin




METHODS— ESD was an academic
multicenterprospectiverandomizeddou-
ble-blind placebo-controlled trial inde-
pendently designed, conducted and
monitored by the investigators of the
ClinicalResearchCenterforRareDiseases
“Aldo & Cele Dacco `” and three diabetol-
ogy units in Italy. The protocol was ap-
proved by the ethical committees of all
institutions. Patients provided written in-
formed consent according to the Declara-
tion of Helsinki. Data were handled and
reported without sponsor involvement.
Authors had full access to data and criti-
cally revised and ﬁnally approved the
manuscript.
The18-to70-year-oldtype2diabetic
subjects with total cholesterol concentra-
tions 135 mg/dl despite lipid-lowering
therapy, serum creatinine 1.5 mg/dl,
and urinary albumin excretion 200 g/
min were eligible for study participation.
Individuals with recent cardiovascular
events, primary hyperlipidemia, or he-
patic or muscle disease; who were preg-
nant or lactating; who were treated with
steroids, immunosuppressive agents, ﬁ-
brates, niacin, or cholestyramine; or who
were unable to provide informed consent
were excluded (ClinicalTrials.gov identi-
ﬁer: NCT00157482).
After a 4-week wash-out from previ-
ous lipid-lowering therapy (if any), and a
2-month run-in with 40 mg/day simva-
statin, eligible patients were randomly al-
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with10mg/dayezetimibeorplacebo.De-
mography and clinical and laboratory
data were recorded at inclusion, random-
ization, and study end.
Laboratory parameters were centrally
measured by an automatic analyzer
(Beckman Synchron CX9). Glycosylated
hemoglobin was measured by high-
performance liquid chromatography
(normal laboratory range 3.53–5.21%;
Beckman System Gold Chromatograph).
Urinaryalbuminexcretionwasmeasuredin
three consecutive overnight urine collec-
tions by nephelometry (Array 360 System;
Beckman, Milan, Italy) in sterile urine.
LDL cholesterol was the primary
outcome. Based on average levels ob-
served in statin-treated type 2 diabetic
patients with normo- or microalbumin-
uria referred to our research center, we
predicted LDL serum levels of 90  12
mg/dl at randomization. Assuming a
20% reduction on ezetimibe and no
change on placebo, 51 patients per
group were required in order to have
80% power to detect a statistically sig-
niﬁcant difference (P  0.05) between
the two study arms in LDL change from
baseline to study end. To account for a
5% dropout rate, 54 patients per group
had to be randomized.
Patients were centrally randomized
to ezetimibe or placebo on a 1:1 ratio
within blocks of four according to a
computer-generated randomization
list. Patients and investigators were
blinded to treatment. Analyses were by
intention to treat. Characteristics of pa-
tients were compared by 
2 test, Fisher
exact test, unpaired t test, or Wilcoxon
rank-sum test as appropriate. Within-
group treatment effects were assessed
byrepeated-measuresANOVAfollowed
by paired t tests or by McNemar 
2 test
(between-group effects by ANCOVA,
adjusting for the measurement at ran-
domization or by 
2 test). The multiple
pairwise comparison issue was ad-
dressed using Bonferroni adjustment.
AnalyseswereperformedusingSASver-
sion 9.1 (SAS Institute, Cary, NC). Data
were expressed as mean  SD or me-
dian (interquartile range) or number
(%) unless otherwise speciﬁed. All P
valuesweretwo-sided.Statisticalsignif-
icance was set at the 0.05 level.
RESULTS— Of 114 screened sub-
jects, 108 fulﬁlled the selection criteria
and were randomized. One patient ran-
domized to ezetimibe eventually with-
drew his consent; thus, 53 patients on
ezetimibe and 54 on placebo completed
the study. Main characteristics at ran-
domization (Table 1) including age (65.7
vs. 65.2 years), proportion of males (63.0
vs. 55.6%), and proportion of current
smokers (44.6 vs. 55.6%) were similar in
the ezetimibe and placebo group, respec-
tively, whereas the proportion of subjects
with a family history of coronary heart
diseasewashigher(51.9vs.29.6%)inthe
ezetimibe group.
LDL and total cholesterol and apoli-
poprotein B signiﬁcantly decreased by
30.9,21.6,and19.6%,respectively,com-
pared with randomization in patients
given ezetimibe, but did not change ap-
preciablyinindividualsonplacebo(Table
1). These trends were signiﬁcantly differ-
ent between groups (P  0.0001 for all
comparisons). At study end, 4.2-fold
more subjects on ezetimibe than on pla-
cebo achieved an LDL level of 70 mg/dl
(Table 1). Serum HDL cholesterol and
triglycerides decreased on ezetimibe but
Table 1—Patients characteristics at randomization (Pre) and at the end of the treatment period (Post) according to study treatment
Variable (unit)
Ezetimibe Placebo
Pre (n  54) Post (n  53) Pre (n  54) Post (n  54)
Clinical parameters
BMI (kg/m
2) 29.0  4.2 28.8  4.3 28.8  4.1 28.9  4.1
Systolic blood pressure (mmHg) 136  13 133  13 131  15 131  15
Diastolic blood pressure (mmHg) 79  77 8  77 8  87 7  7
Metabolic parameters
Serum glucose (mg/dl) 160  44 168  43 162  50 159  44
HbA1C (%) 5.8  1.5 5.5  1.2 5.5  1.1 5.5  1.2
Renal function
Serum creatinine (mg/dl) 0.90  0.18 0.91  0.17 0.87  0.20 0.88  0.21
Serum urea (mg/dl) 42  12 43  12 39  12 39  11
Urinary albumin excretion (g/min) 5.2 (2.8–10.3) 4.7 (3.3–11.8) 4.6 (3.4–7.2) 4.7 (3.3–9.6)
Lipids
Total cholesterol (mg/dl) 162  36 124  30* 154  30 158  32‡
HDL cholesterol (mg/dl) 48  11 45  12* 50  12 50  11§
LDL cholesterol (mg/dl) 99  31 66  22* 91  28 94  32‡
LDL 70 mg/dl 7 (13.0) 38 (71.7)† 14 (25.9) 9 (16.7)†‡
Triglycerides (mg/dl) 123  95 108  77 106  65 104  62§
Apolipoprotein A (mg/dl) 134  23 138  27 139  20 143  23
Apolipoprotein B (mg/dl) 83  22 64  18* 81  23 81  22‡
Safety parameters
Aspartate transaminase (IU/l) 23  72 4  92 1  52 1  6
Alanine transaminase (IU/l) 25  10 27  10 23  92 3  8
-Glutamyl transferase (IU/l) 33  39 35  37 30  30 29  27
Creatinine phosphokinase (IU/l) 147  140 143  120 113  60 115  70
DataaremeansSD,medians(interquartilerange),orn(%).*P0.01and†P0.0001vs.Pre(BonferroniadjustedpairedttestorMcNemar
2test).‡P0.0001
and §0.05 vs. ezetimibe (ANCOVA or 
2 test).
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icantly different between groups (Table
1). After randomization, urinary albumin
excretion did not appreciably change in
both groups (Table 1).
Treatment was well tolerated. No sig-
niﬁcant increases in serum creatinphos-
phokinase and transaminase levels were
observedinbotharms(Table1).Fourpa-
tients on ezetimibe and one on placebo
had transient sinus bradycardia that re-
coveredspontaneouslywithouttreatment
withdrawal.
CONCLUSIONS — In type 2 dia-
betic patients with normo- or microalbu-
minuria and persistent dyslipidemia
despite background therapy with a ﬁxed
dose of simvastatin, 2-month add-on
treatment with ezetimibe signiﬁcantly
ameliorated the lipid proﬁle and, com-
paredwithplacebo,increasedbyfourfold
the proportion of patients achieving the
LDL target currently recommended for
people with diabetes (7,8). This effect ex-
ceeded the lipid-lowering effect of com-
binedtherapyreportedinpreviousseries,
most likely because here we compared
ezetimibe with placebo in subjects given
the same dosage of simvastatin, whereas
previous studies compared combined
therapy with simvastatin given at higher
dosages (2) or with another more power-
ful statin (4,5). However, our study was
underpowered to assess whether choles-
terol reduction may affect albuminuria
perse(9–11),independentof3-hydroxy-
3methyl-glutaril-coenzyme A (HMG-
CoA) inhibition (12). As previously
reported (13), combined treatment was
remarkably well tolerated. However, be-
cause there were four cases of transient
sinus bradycardia in the ezetimibe arm,
this therapeutic option should be consid-
ered with caution in subjects with brady-
arrhythmias. In conclusion, adding
ezetimibe to simvastatin therapy helps
improve the pro-atherogenic lipoprotein
proﬁle in type 2 diabetic patients while
avoiding the drawbacks of maximizing
statin doses.
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